Killing Cancer At Its Stem Cell Origin

Killing Cancer At Its Stem Cell Origin

Killing Cancer When it comes to killing cancer, eradicating every single cell is the goal. But did you know there are different kinds of cancer cells? One specific type, called cancer stem cells (CSC), is catching the eye of drug developers. Discovered more than a...
On A Tumor’s Turf

On A Tumor’s Turf

TACKLING THE SPACE AROUND SOLID TUMORS Covering the science behind T-cell-based immunotherapies has been the name of the game for our past couple of issues. CAR-T and TCR therapies show significant promise in early phase blood cancer clinical trials, but what about...
Next-Generation CAR-T

Next-Generation CAR-T

The Race Is On Our last WEEKLY—Hacking the Immune Response—unveiled the science behind CAR-T and TCR, two immunotherapies under the microscope of the mainstream press. The well-deserved media attention highlights the ability of these “living drugs” to recognize and...
Hacking The Immune Response

Hacking The Immune Response

BIOPHARMA’S DARLING Immunotherapy is the current biopharma darling, garnering massive investment and media attention. Ranging from monoclonal antibodies to engineered T-cells, companies are rapidly learning how to harness the power of the immune system to fight...
Catching The First Drop Of Cancer

Catching The First Drop Of Cancer

The Latest In Cancer Diagnostics Hearing the words “it might be cancer” paired with your doctor’s perplexed look is enough to send shockwaves through your body. Getting to the heart of a diagnosis usually requires a surgical biopsy—removal and...